CPHI ShangHai 2025
From June 24 to 26, 2025, the 23rd CPhI China was successfully held at the Shanghai New International Expo Centre!JYMed President Mr. Yao Zhiyong, together with the company’s senior leadership team, attended the event in person. The team engaged directly with the full lifecycle of GLP-1 peptide drugs, offering expert insights across six key areas: R&D, CMC, manufacturing, quality control, supply chain, and business development.
During meetings with clients, JYMed demonstrated both sincerity and strong results. Our executive team was deeply involved, delivering end-to-end professional support and exploring partnership opportunities face-to-face.By establishing a direct-response chain led by top management, we addressed challenges from process bottlenecks to supply risks with flexible, customizable collaboration models—turning each meeting into a strategic touchpoint built on trust.
Where we step forward marks not only the end of a peptide chain but the beginning of better health.With technological innovation as our oar and customer success as our compass, JYMed is committed to becoming a global leader in peptide CRDMO services.We look forward to co-creating value, achieving win-win partnerships, and contributing to the healthy development of the global peptide industry.
About JYMed
JYMed is a science-driven pharmaceutical company specializing in the development, manufacturing, and commercialization of peptide-based products. We offer end-to-end CDMO services for pharmaceutical, cosmetic, and veterinary partners worldwide.
Our product portfolio includes a wide range of peptide APIs, including Semaglutide and Tirzepatide, both of which have successfully completed U.S. FDA DMF filings.
Our manufacturing arm, Hubei JXBio, operates cutting-edge peptide API production lines that meet cGMP standards from both the U.S. FDA and China’s NMPA. The site features 10 large- and pilot-scale lines and is supported by a robust QMS and comprehensive EHS framework.
JXBio has passed GMP audits by the U.S. FDA and China’s NMPA and is recognized by leading pharmaceutical companies for its commitment to safety, quality, and environmental responsibility.
MAIN PRODUCTS
Let’s Connect
To learn more about our capabilities or to schedule a meeting during the show:
•Global API & Cosmetic Inquiries: +86-150-1352-9272
•API Registration & CDMO Services (U.S. & EU): +86-158-1868-2250
•Email: jymed@jymedtech.com
•Address: Floors 8 & 9, Building 1, Shenzhen Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen, China.